Alaunos Therapeutics, Inc.
TCRT- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001107421
No open-market purchases or sales by Alaunos Therapeutics, Inc. insiders were filed in the last 90 days; 29 institutions reported holding it in 13F filings for Q2 2026, worth $204.4K in total; no superinvestor holds it.
Q2 2025 vs. Q1 2025
How the institutions holding Alaunos Therapeutics, Inc. changed between Q1 2025 and Q2 2025.
All holders in Q2 2025All holders in Q1 2025
| Measure | Q1 2025 | Q2 2025 | Change |
|---|---|---|---|
| Holders | 29 | 28 | −1 |
| Shares | 70.7K | 71.1K | +347 (+0.5%) |
| Value | $103.4K | $344.6K | +$241.2K (+233.4%) |
New holders (3)
Institutions that held Alaunos Therapeutics, Inc. at the end of Q2 2025 but not at the end of Q1 2025.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Raymond James Financial Inc | 99 | $480 | 0.00% |
| Key Financial Inc | 24 | $116 | 0.00% |
| JPMorgan Chase & Co | 3 | $15 | 0.00% |
Sold out (4)
Institutions that held Alaunos Therapeutics, Inc. at the end of Q1 2025 and filed for Q2 2025 without it.
| Institution | Shares, Q1 2025 | Value, Q1 2025 |
|---|---|---|
| West Paces Advisors Inc. | 10 | $15 |
| PSI Advisors, LLC | 6 | $9 |
| Tidemark, LLC | 2 | $3 |
| Royal Bank of Canada | 100 | $0 |